These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 11504634)
21. Functional domains essential for Gs activity in prostaglandin EP2 and EP3 receptors. Sugimoto Y; Nakato T; Kita A; Hatae N; Tabata H; Tanaka S; Ichikawa A Life Sci; 2003 Dec; 74(2-3):135-41. PubMed ID: 14607240 [TBL] [Abstract][Full Text] [Related]
22. Prostaglandin E₂ inhibits human lung fibroblast chemotaxis through disparate actions on different E-prostanoid receptors. Li YJ; Wang XQ; Sato T; Kanaji N; Nakanishi M; Kim M; Michalski J; Nelson AJ; Sun JH; Farid M; Basma H; Patil A; Toews ML; Liu X; Rennard SI Am J Respir Cell Mol Biol; 2011 Jan; 44(1):99-107. PubMed ID: 20203295 [TBL] [Abstract][Full Text] [Related]
23. EP1- and EP3-receptors mediate prostaglandin E2-induced constriction of porcine large cerebral arteries. Jadhav V; Jabre A; Lin SZ; Lee TJ J Cereb Blood Flow Metab; 2004 Dec; 24(12):1305-16. PubMed ID: 15625406 [TBL] [Abstract][Full Text] [Related]
24. Agonist-induced phosphorylation by G protein-coupled receptor kinases of the EP4 receptor carboxyl-terminal domain in an EP3/EP4 prostaglandin E(2) receptor hybrid. Neuschäfer-Rube F; Oppermann M; Möller U; Böer U; Püschel GP Mol Pharmacol; 1999 Aug; 56(2):419-28. PubMed ID: 10419563 [TBL] [Abstract][Full Text] [Related]
25. Effects of PGE2 EP3/EP4 receptors on bladder dysfunction in mice with experimental autoimmune encephalomyelitis. Xue R; Jia Z; Kong X; Pi G; Ma S; Yang J Am J Physiol Renal Physiol; 2013 Dec; 305(12):F1656-62. PubMed ID: 24154697 [TBL] [Abstract][Full Text] [Related]
26. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Timoshenko AV; Xu G; Chakrabarti S; Lala PK; Chakraborty C Exp Cell Res; 2003 Oct; 289(2):265-74. PubMed ID: 14499627 [TBL] [Abstract][Full Text] [Related]
27. Growth regulation of primary human keratinocytes by prostaglandin E receptor EP2 and EP3 subtypes. Konger RL; Malaviya R; Pentland AP Biochim Biophys Acta; 1998 Feb; 1401(2):221-34. PubMed ID: 9531979 [TBL] [Abstract][Full Text] [Related]
28. Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Walch L; de Montpreville V; Brink C; Norel X Br J Pharmacol; 2001 Dec; 134(8):1671-8. PubMed ID: 11739243 [TBL] [Abstract][Full Text] [Related]
30. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Meja KK; Barnes PJ; Giembycz MA Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of noradrenaline release in the rat vena cava via prostanoid receptors of the EP3-subtype. Molderings G; Malinowska B; Schlicker E Br J Pharmacol; 1992 Oct; 107(2):352-5. PubMed ID: 1330175 [TBL] [Abstract][Full Text] [Related]
32. Development of an in vivo active, dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostere. Downey JD; Saleh SA; Bridges TM; Morrison RD; Daniels JS; Lindsley CW; Breyer RM Bioorg Med Chem Lett; 2013 Jan; 23(1):37-41. PubMed ID: 23218714 [TBL] [Abstract][Full Text] [Related]